The brands acquired include Doan's, Bufferin, Nupercainal ointment, Cruex nail gel, comtrex and myoflex. These are mainly used in treating cough-and-cold, pain and dermatology issues.
"We are extremely excited to be entering the branded consumer health arena through these brands and embarking upon the next avenue of growth for our OTC business in the US," Executive Vice-President and Head of Dr Reddy's in the US Alok Sonig said.
These legacy products enjoy strong brand equity built over several decades, he added.
Dr Reddy's shares today ended 0.92 per cent higher at Rs 3,052.95 apiece on BSE.
